Biotech Values

[DewDiligence]

(LGND)—GSK reported today that the first of two phase-3 trials testing SoC ± Promacta in HCV patients with thrombocytopenia, called ENABLE-1, hit its primary endpoint by showing a statsig increase in SVR (http://www.gsk.com/investors/reports/q22011/q22011.pdf page 4).

ENABLE-2, a clone of ENABLE-1, is due to report data any day. The clinicaltrials.gov entries for these trials are in http://www.clinicaltrials.gov/ct2/show/NCT00516321 and http://www.clinicaltrials.gov/ct2/show/NCT00529568 .